Design and therapeutic application of matrix metalloproteinase inhibitors
about
sameAs
Meta-analysis of association of the matrix metalloproteinase 2 (-735 C/T) polymorphism with cancer riskDeterminants of the inhibition of a Taiwan habu venom metalloproteinase by its endogenous inhibitors revealed by X-ray crystallography and synthetic inhibitor analoguesInsights from Selective Non-phosphinic Inhibitors of MMP-12 Tailored to Fit with an S1' Loop Canonical ConformationStructure of the Bacterial Deacetylase LpxC Bound to the Nucleotide Reaction Product Reveals Mechanisms of Oxyanion Stabilization and Proton TransferSimple Pseudo-dipeptides with a P2' Glutamate: A NOVEL INHIBITOR FAMILY OF MATRIX METALLOPROTEASES AND OTHER METZINCINSAn integrated computational approach to rationalize the activity of non-zinc-binding MMP-2 inhibitorsProteolysis controls endogenous substance P levelsMMpI: A WideRange of Available Compounds of Matrix Metalloproteinase InhibitorsSynthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: Developing a structure–activity relationshipPyrone-Based Inhibitors of Metalloproteinase Types 2 and 3 May Work as Conformation-Selective InhibitorsIdentification of novel non-hydroxamate anthrax toxin lethal factor inhibitors by topomeric searching, docking and scoring, and in vitro screening.Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.Proteomic profiling of metalloprotease activities with cocktails of active-site probes.Combinatorial strategies for targeting protein families: application to the proteases.From sensors to silencers: quinoline- and benzimidazole-sulfonamides as inhibitors for zinc proteasesA macrophage cell model for selective metalloproteinase inhibitor designZinc-binding groups modulate selective inhibition of MMPs.Activation of sulfonate ester based matrix metalloproteinase proinhibitors by hydrogen peroxideIdentifying chelators for metalloprotein inhibitors using a fragment-based approach.Enzymatic activation of a matrix metalloproteinase inhibitorInvestigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors.Conformational variability of matrix metalloproteinases: beyond a single 3D structure.Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors.Hydrogen peroxide activated matrix metalloproteinase inhibitors: a prodrug approachInvestigating chelating sulfonamides and their use in metalloproteinase inhibitors(2RS)-3-Hydr-oxy-2-methyl-2-(2-pyrid-yl)imidazolidine-4-one.Development of a comprehensive, validated pharmacophore hypothesis for anthrax toxin lethal factor (LF) inhibitors using genetic algorithms, Pareto scoring, and structural biology.3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.Immuno-PET imaging of tumor endothelial marker 8 (TEM8)Curcumin binds in silico to anti-cancer drug target enzyme MMP-3 (human stromelysin-1) with affinity comparable to two known inhibitors of the enzyme.A peptidomics strategy to elucidate the proteolytic pathways that inactivate peptide hormones.Matrix metalloproteinases and collagen catabolism.Evaluating prodrug strategies for esterase-triggered release of alcoholsSystemic delivery of protein nanocages bearing CTT peptides for enhanced imaging of MMP-2 expression in metastatic tumor modelsMetalloproteinases: their role in arthritis and potential as therapeutic targets.Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis.Peptides with anticancer use or potential.
P2860
Q26771838-D9A3EEF6-323A-4C46-9F80-ABD75863CA90Q27639192-3CA0ACE8-EB86-4CDA-AEBB-B3DAE06D8188Q27664274-059522CA-84FB-4A69-A490-AF5411465CCBQ27680209-47C9F0E6-F54A-4E1B-BB31-BC100A7D549AQ27681108-4AF61221-B31E-476C-8CB8-7F4DE3E10191Q28485109-873E10FA-15B6-40C9-84DB-C4B3EF34D01DQ28534739-F122DDF3-0AA4-4352-A2A3-137C4F5242F3Q28553432-93A95B52-AB19-4BBD-AF7D-353E8EEE82EAQ29012564-5F10F197-2756-478C-99A8-CE1A109243AFQ30039761-4239D9F9-0A30-4F0D-B776-5B76B104EAC8Q30478430-81A1FE83-E432-428C-AEB5-F9BFCBE227F4Q30540523-2B0252B1-B9EE-4BA7-AB8A-C29EAF298688Q33237686-6F5C76C6-25CB-4D2F-BCBA-64308B7C81DFQ33288760-9976F3D4-BD2A-4643-B010-5E5035258CC3Q33589093-4B621404-D4F2-472F-993D-F687EF04C7C7Q33680972-499E18A5-BBF0-4C13-A6C5-B50F3D802CC1Q33718245-48C6462F-6923-4799-91C2-7EE051A886BFQ33737922-B5E29EF9-37D0-4F8B-9C89-653D6D285F6DQ33781388-ABEB2115-2C42-446A-B812-32F17D80D21BQ33839227-D8A8B444-0DC5-475E-A04F-B33A02A21D9EQ33934129-4DA9A9C6-1DE9-407C-9D85-BBBBC31BC241Q33936554-9EAA0632-8188-4DED-AB2D-1A07A3C77BB5Q33986501-7C6271E2-C13B-420D-8B3E-D41D176B720BQ34084599-9CB24123-6C9C-4DDE-A11D-4282F68457EDQ34175711-1CB5152C-4DEF-4B85-866D-348AFE8966E8Q34192005-1BD64132-5C58-4B1D-83AB-E09D666231C5Q34192481-F7049EEA-5548-43C0-9857-06FCADC21846Q34266092-C36FB546-B346-4540-B2DD-DA990394086CQ34304133-839EC5AF-7A8A-4F3F-B100-1B7F15E31BCAQ34336500-7C89D226-7F70-4D31-85E2-ADBF2BEDBB7FQ34473434-EAC068E4-1775-4E09-A945-9C9A3D839E94Q34673409-9A7F476F-21C7-4A67-B4D6-56497CD6C4AAQ34795373-C10E3F78-3401-4576-B956-4734F147F945Q34850104-4B5AC2C6-599A-4939-A43B-9E40D6719B71Q34912678-DB87E2D2-D070-4F45-9F09-2E507F940F8DQ35016398-4761DFF3-D1D0-4477-8E35-114070A4AA98Q35056019-B2FB872C-99AC-4A0F-A36A-F74748B50F3BQ35112695-3EDCCB02-566F-406A-9E02-331FF9F12085Q35155417-3DD08ABB-D57F-41D6-9036-001FF44D55C8Q35167010-CED7B58B-43BA-410F-B621-11A04F17CA1A
P2860
Design and therapeutic application of matrix metalloproteinase inhibitors
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Design and therapeutic application of matrix metalloproteinase inhibitors
@ast
Design and therapeutic application of matrix metalloproteinase inhibitors
@en
Design and therapeutic application of matrix metalloproteinase inhibitors
@nl
type
label
Design and therapeutic application of matrix metalloproteinase inhibitors
@ast
Design and therapeutic application of matrix metalloproteinase inhibitors
@en
Design and therapeutic application of matrix metalloproteinase inhibitors
@nl
prefLabel
Design and therapeutic application of matrix metalloproteinase inhibitors
@ast
Design and therapeutic application of matrix metalloproteinase inhibitors
@en
Design and therapeutic application of matrix metalloproteinase inhibitors
@nl
P2093
P3181
P356
P1433
P1476
Design and therapeutic application of matrix metalloproteinase inhibitors
@en
P2093
P304
P3181
P356
10.1021/CR9804543
P407
P577
1999-09-08T00:00:00Z